Definium Therapeutics announced the pricing of an upsized underwritten public offering of 20,588,236 common shares at a public offering price of $34 per share.
The gross proceeds to Definium from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be about $700 million. Definium has also granted the underwriters a 30-day option to purchase up to an additional 3,088,235 common shares at the public offering price, less underwriting discounts and commissions.
All of the common shares are being offered by Definium. The offering is expected to close on or about June 25, 2026, subject to customary closing conditions. No distribution under the offering will occur in Canada or to a person resident in Canada.
Definium plans to use the net proceeds from the offering for the research and development of its product candidates, preparation activities for the potential commercialization of DT120 ODT if approved, and working capital and general corporate purposes.
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. The company’s mission is to apply scientific rigor to psychedelics with the goal of developing accessible treatments that can support healing at scale.
Based in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.
Support: J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities are serving as joint lead bookrunners for the offering. Evercore ISI and Stifel are also serving as bookrunners. Oppenheimer & Co. and LifeSci Capital are serving as co-lead managers.
